Royalty Pharma PLC

Latest Results (13.11.2025):

Royalty Pharma PLC reported robust financial results for Q1 2025, demonstrating strong growth and resilient operational performance. The company achieved double-digit increases in both Portfolio and Royalty Receipts, enhanced its liquidity position with significant operating cash flows, executed an aggressive share repurchase plan, and raised full-year guidance for Portfolio Receipts, reinforcing its positive business momentum.

Strong Revenue Growth

In Q1 2025, Portfolio Receipts grew by 17% to $839 million, and Royalty Receipts increased by 12% to $788 million. Key drivers included robust performance from its cystic fibrosis franchise, Trelegy, and Xtandi, along with milestone contributions such as a $27 million payment related to Airsupra.

Operational Improvements

Adjusted EBITDA increased 12% to $738 million and Portfolio Cash Flow grew by 5% to reach $611 million. These liquidity measures underscore the company's ability to generate substantial cash from its operations, supporting further investments and shareholder returns.

Capital Deployment & Share Repurchases

Royalty Pharma repurchased 23 million Class A ordinary shares for $723 million during the quarter under a dynamic capital allocation strategy. Additionally, the company deployed $101 million towards capital projects, including an R&D funding arrangement with Biogen for the development of litifilimab.

Enhanced Guidance & Future Outlook

Buoyed by continued momentum, Royalty Pharma raised its full-year 2025 guidance for Portfolio Receipts to a range of $2,975 to $3,125 million. The company remains focused on further capital allocation efficiency, upcoming strategic acquisitions, and a promising pipeline of clinical and regulatory advancements.